| Name | Title | Contact Details |
|---|
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Varian Medical Systems` vision is a world without fear of cancer. To meet this challenge, we equip the world with new tools for fighting cancer. Since the 1950s we have been producing tools that harness the power of X-ray energy to benefit humankind. Our history is one of pioneering developments in the fields of radiotherapy, radiosurgery, X-ray tube technology, digital image detectors, cargo screening, and non-destructive testing. Today, we have a robust product portfolio and long-standing relationships with many of the world`s leading clinicians. As Varian continues to grow, our staff of over 6,500 people in 70 sales and support offices around the globe is developing innovative, cost-effective solutions that help make the world a healthier place. Varian reserves the right to remove any comment for any reason and ban any user from its page at is sole discretion. Varian does not endorse user comments on its page and cannot confirm their accuracy. User comments do not necessarily represent the ideas, thoughts, beliefs, opinions or views of Varian, or any of its affiliates.
Discover Research Inc is a Beaumont, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Southwest General is a 350-bed, non-profit hospital serving southwestern Cuyahoga, northern Medina and eastern Lorain counties. Founded in 1920 by residents of the surrounding communities, Southwest General has a rich history of community partnership and a deep commitment to the health and well-being of the residents it serves. Southwest General is home to nationally recognized physicians, state-of-the-art technology and a full range of medical, surgical and emergency services, including a Level III trauma center. Additionally, patients and families benefit from an extensive program of social services and support groups that provide mental, emotional and spiritual support. All services at Southwest General are provided with an eye toward excellence and individual attention. This is best expressed in Southwest General`s mission statement: Health is our Passion. Quality is our Focus. Compassion is our Way.
DecisionLine Clinical Research is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.